Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 29-Aug-23 5:04 PM View:  | Hall Ashley Chief Development Officer | Reneo Pharmaceuticals, Inc. (RPHM) | 28-Aug-23 | Option Exercise | 15,625 | $1.80 | $28,125.00 | 39% 39.6K to 55.23K | |
| 29-Aug-23 5:04 PM View: | Hall Ashley Chief Development Officer | Reneo Pharmaceuticals, Inc. (RPHM) | 28-Aug-23 | Option Sale | 15,625 | $6.28 | $98,057.80 | (28%) 55.23K to 39.6K | |
| 27-Jul-23 5:16 PM View: | Grey Michael G Executive Chairman Director | Reneo Pharmaceuticals, Inc. (RPHM) | 26-Jul-23 | Gift | 50,000 | -- | -- | (7%) 678.85K to 628.85K | |
| 23-Jun-23 7:15 PM View: | Novo A/s 10% Owner | Reneo Pharmaceuticals, Inc. (RPHM) | 23-Jun-23 | Sale | 100,000 | $7.10 | $709,740.00 | (3%) 3.43M to 3.33M | |
| 10-May-23 5:47 PM View: | O'Donnell Niall Director | Reneo Pharmaceuticals, Inc. (RPHM) | 08-May-23 | Private Purchase | 125,000 | $8.00 | $1,000,000.00 | 6% 2.06M to 2.19M | |
| 02-Sep-22 5:12 PM View: | Cruse Michael Chief Operating Officer | Reneo Pharmaceuticals, Inc. (RPHM) | 01-Sep-22 | Private Purchase | 7,500 | $3.39 | $25,447.50 | 20% 37.95K to 45.45K | |
| 02-Sep-22 5:10 PM View: | Grey Michael G Executive Chairman Director | Reneo Pharmaceuticals, Inc. (RPHM) | 31-Aug-22 | Option Exercise | 50,000 | $1.97 | $98,500.00 | 9% 578.85K to 628.85K | |
| 31-Aug-22 5:47 PM View: | Cruse Michael Chief Operating Officer | Reneo Pharmaceuticals, Inc. (RPHM) | 31-Aug-22 | Purchase | 3,212 | $3.21 | $10,307.30 | 9% 34.74K to 37.95K | |
| 31-Aug-22 5:47 PM View: | Cruse Michael Chief Operating Officer | Reneo Pharmaceuticals, Inc. (RPHM) | 30-Aug-22 | Purchase | 1,845 | $3.19 | $5,892.56 | 6% 32.9K to 34.74K | |
| 31-Aug-22 5:47 PM View: | Cruse Michael Chief Operating Officer | Reneo Pharmaceuticals, Inc. (RPHM) | 30-Aug-22 | Purchase | 975 | $3.16 | $3,081.00 | 3% 31.92K to 32.9K | |
| 31-Aug-22 5:47 PM View: | Cruse Michael Chief Operating Officer | Reneo Pharmaceuticals, Inc. (RPHM) | 29-Aug-22 | Private Purchase | 83 | $3.24 | $268.92 | < 1% 30.7K to 30.78K | |
| 31-Aug-22 5:47 PM View: | Cruse Michael Chief Operating Officer | Reneo Pharmaceuticals, Inc. (RPHM) | 29-Aug-22 | Purchase | 1,140 | $3.24 | $3,693.60 | 4% 30.78K to 31.92K | |
| 13-Dec-22 6:07 PM View: | Dorenbaum Alejandro Chief Medical Officer | Reneo Pharmaceuticals, Inc. (RPHM) | 12-Aug-22 | Gift | 22,348 | -- | -- | (43%) 52.35K to 30.0K | |
| 14-Dec-21 4:32 PM View: | Jindal Vineet R. Chief Financial Officer | Reneo Pharmaceuticals, Inc. (RPHM) | 10-Dec-21 | Grant | 30,000 | -- | -- | 455% 6.6K to 36.6K | |
| 14-Dec-21 4:28 PM View: | Cruse Michael Senior VP-Corporate Operations | Reneo Pharmaceuticals, Inc. (RPHM) | 10-Dec-21 | Grant | 25,000 | -- | -- | 610% 4.1K to 29.1K | |
| 14-Dec-21 4:31 PM View: | Flesher Gregory J. President and CEO Director | Reneo Pharmaceuticals, Inc. (RPHM) | 10-Dec-21 | Grant | 100,000 | -- | -- | 1042% 9.6K to 109.6K | |
| 14-Dec-21 4:30 PM View: | Dorenbaum Alejandro Chief Medical Officer | Reneo Pharmaceuticals, Inc. (RPHM) | 10-Dec-21 | Grant | 30,000 | -- | -- | 134% 22.35K to 52.35K | |
| 15-Nov-21 7:49 PM View: | Hall Ashley Chief Development Officer | Reneo Pharmaceuticals, Inc. (RPHM) | 12-Nov-21 | Grant | 30,000 | -- | -- | 100% 0 to 30.0K | |
| 26-Aug-21 5:54 PM View: | Jindal Vineet R. Chief Financial Officer | Reneo Pharmaceuticals, Inc. (RPHM) | 25-Aug-21 | Market Purchase | 5,000 | $7.44 | $37,176.50 | 100% 0 to 5.0K | (5%) |
| 26-Aug-21 5:51 PM View: | Cruse Michael Senior VP-Corporate Operations | Reneo Pharmaceuticals, Inc. (RPHM) | 25-Aug-21 | Market Purchase | 2,500 | $7.45 | $18,616.00 | 100% 0 to 2.5K | (5%) |
| 26-Aug-21 5:52 PM View: | Flesher Gregory J. President and CEO Director | Reneo Pharmaceuticals, Inc. (RPHM) | 25-Aug-21 | Market Purchase | 8,000 | $8.00 | $64,000.00 | 100% 0 to 8.0K | (12%) |
| 15-Jul-21 5:33 PM View: | Johnson Wendy S. Chief Development Officer | Reneo Pharmaceuticals, Inc. (RPHM) | 14-Jul-21 | Market Sale | 111,736 | $8.50 | $949,756.00 | (100%) 111.74K to 0 | (2%) |
| 15-Jul-21 5:34 PM View: | Muralidhar Bali Director | Reneo Pharmaceuticals, Inc. (RPHM) | 14-Jul-21 | Market Purchase | 111,736 | $8.50 | $949,756.00 | 6% 1.96M to 2.07M | 2% |
| 09-Jul-21 6:52 PM View: | Johnson Wendy S. Chief Development Officer | Reneo Pharmaceuticals, Inc. (RPHM) | 08-Jul-21 | Option Exercise | 111,736 | $1.97 | $220,120.00 | 100% 0 to 111.74K | |
| 25-Jun-21 9:00 AM View: | Muralidhar Bali Director | Reneo Pharmaceuticals, Inc. (RPHM) | 23-Jun-21 | Market Purchase | 20,710 | $9.28 | $192,245.00 | 1% 1.94M to 1.96M | 4% |
| 23-Jun-21 8:33 AM View: | Muralidhar Bali Director | Reneo Pharmaceuticals, Inc. (RPHM) | 22-Jun-21 | Market Purchase | 14,615 | $8.72 | $127,487.00 | < 1% 1.93M to 1.94M | 5% |
| 23-Jun-21 8:33 AM View: | Muralidhar Bali Director | Reneo Pharmaceuticals, Inc. (RPHM) | 21-Jun-21 | Market Purchase | 32,659 | $9.03 | $294,927.00 | 2% 1.89M to 1.93M | 1% |
| 10-Jun-21 9:00 AM View: | Muralidhar Bali Director | Reneo Pharmaceuticals, Inc. (RPHM) | 08-Jun-21 | Market Purchase | 16,605 | $9.50 | $157,709.00 | < 1% 1.88M to 1.89M | 2% |
| 07-Jun-21 8:53 AM View: | Muralidhar Bali Director | Reneo Pharmaceuticals, Inc. (RPHM) | 04-Jun-21 | Market Purchase | 257 | $9.42 | $2,422.02 | < 1% 1.88M to 1.88M | 3% |
| 07-Jun-21 8:53 AM View: | Muralidhar Bali Director | Reneo Pharmaceuticals, Inc. (RPHM) | 03-Jun-21 | Market Purchase | 12,100 | $9.25 | $111,943.00 | < 1% 1.87M to 1.88M | 5% |
| 02-Jun-21 10:37 AM View: | Muralidhar Bali Director | Reneo Pharmaceuticals, Inc. (RPHM) | 28-May-21 | Private Purchase | 14 | $9.50 | $133.00 | < 1% 1.87M to 1.87M | |
| 28-May-21 4:10 PM View: | Muralidhar Bali Director | Reneo Pharmaceuticals, Inc. (RPHM) | 27-May-21 | Market Purchase | 1,120 | $9.26 | $10,369.30 | < 1% 1.86M to 1.87M | 4% |
| 28-May-21 4:10 PM View: | Muralidhar Bali Director | Reneo Pharmaceuticals, Inc. (RPHM) | 26-May-21 | Market Purchase | 5,915 | $9.38 | $55,495.10 | < 1% 1.86M to 1.86M | 3% |
| 15-Apr-21 6:16 PM View: | New Enterprise Associates 1... 10% Owner | Reneo Pharmaceuticals, Inc. (RPHM) | 13-Apr-21 | Purchase | 666,666 | $15.00 | $9,999,990.00 | 16% 4.12M to 4.79M | |
| 15-Apr-21 4:10 PM View: | Grey Michael G Executive Chairman Director | Reneo Pharmaceuticals, Inc. (RPHM) | 13-Apr-21 | Conversion | 20,162 | -- | -- | 4% 558.68K to 578.85K | |
| 14-Apr-21 4:44 PM View: | Novo A/s 10% Owner | Reneo Pharmaceuticals, Inc. (RPHM) | 13-Apr-21 | Conversion | 2,763,710 | -- | -- | 100% 0 to 2.76M | |
| 15-Apr-21 4:15 PM View: | Muralidhar Bali Director | Reneo Pharmaceuticals, Inc. (RPHM) | 13-Apr-21 | Conversion | 1,658,230 | -- | -- | 100% 0 to 1.66M | |
| 15-Apr-21 4:16 PM View: | O'Donnell Niall Director | Reneo Pharmaceuticals, Inc. (RPHM) | 13-Apr-21 | Conversion | 1,863,710 | -- | -- | 100% 0 to 1.86M | |
| 15-Apr-21 6:16 PM View: | New Enterprise Associates 1... 10% Owner | Reneo Pharmaceuticals, Inc. (RPHM) | 13-Apr-21 | Conversion | 4,118,830 | -- | -- | 100% 0 to 4.12M | |
| 14-Apr-21 4:44 PM View: | Novo A/s 10% Owner | Reneo Pharmaceuticals, Inc. (RPHM) | 13-Apr-21 | Purchase | 666,666 | $15.00 | $9,999,990.00 | 24% 2.76M to 3.43M | |
| 15-Apr-21 4:15 PM View: | Muralidhar Bali Director | Reneo Pharmaceuticals, Inc. (RPHM) | 13-Apr-21 | Purchase Duplicate | 200,000 | $15.00 | $3,000,000.00 | 12% 1.66M to 1.86M | |
| 15-Apr-21 4:16 PM View: | O'Donnell Niall Director | Reneo Pharmaceuticals, Inc. (RPHM) | 13-Apr-21 | Purchase | 200,000 | $15.00 | $3,000,000.00 | 11% 1.86M to 2.06M | |
| 13-Apr-21 5:54 PM View: | Rivervest Venture Fund Iii,... 10% Owner | Reneo Pharmaceuticals, Inc. (RPHM) | 09-Apr-21 | Conversion | 1,929,880 | -- | -- | 50% 3.87M to 5.8M | |
| 13-Apr-21 5:54 PM View: | Rivervest Venture Fund Iii,... 10% Owner | Reneo Pharmaceuticals, Inc. (RPHM) | 09-Apr-21 | Purchase | 200,000 | $15.00 | $3,000,000.00 | 3% 5.8M to 6.0M |
